I have been in touch with Prof Charlie Gourley regarding where we are at with Using Trametanib in Low Grade OC. He has very kindly updated me and said this -
“Re trametinib, the long term goal is to persuade the drug company who make it (Novartis) to go for a licensing application on the basis of our trial data so it gets licensed and thus can be given to patients with low grade serous ovarian cancer (although in each country a funding application will also need to be made e.g. to NICE). David Gershenson and I are currently in discussion with them about this.
Until then I am trying to get it funded through an IPTR (known as an IFR or individual funding request in England) for one of my patients just now. We can do that because the drug is already licensed for another cancer (melanoma). I’m not sure how successful that will be but ladies can ask their oncologists to do the same on the basis of the data that were presented in Barcelona. The paper hasn’t been published yet. We will be submitting it soon. Anyway, that is where we are right now.”
I hope that will be of help to those wondering how to access this drug.
Best wishes
Diane xx